University of Florida Research Foundation Inc

Cv Therapeutics, Inc.

Betastem Therapeutics, Inc.

Bartelmez, Stephen H.

Maria B Grant

Nicholas S Bodor

Josef Neu

Luiz Belardinelli

Edward William Scott

Ashay D Bhatwadekar

Debra Carnegie

Stephen H Bartelmez

W Stratford May

According to one embodiment, a nutritional supplement for suppressing an appetite while maintaining muscle mass of a subject during weight loss is provided. The nutritional supplement includes beta-hydroxy beta-methylbutyric acid (HMB), chromium, and

Nutritional supplement for weight management

Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-&#x3b2; expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-&#x3b2; blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-&#x3b2; blocking agent and treated cells are co-administered to a subject in need thereof.

Enhancing vessel lesion homing and repair potential of stem cells

The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation

Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts.

Modulating angiogenesis

The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine&#x21c4;pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

Compounds and method for the prevention and treatment of diabetic retinopathy

The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridinepyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

This invention concerns methods for identifying Aadenosine receptor agonists and antagonists as well as methods for using Aadenosine receptor antagonists to treat cell proliferation orders mediated by the Aadenosine receptor.

Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation

The subject invention provides novel methods and materials for treating diabetic retinopathy. One embodiment of the subject invention involves the co-administration of a somatostatin, or analogue thereof, and a thryoid-related substance such as thyroxine. Somatostatin or thyroid-related substance can be administered in combination, or separately through the same or different modes of administration.

Growing community of inventors

Fairfield, FL, United States of America

Maria B Grant